In the TKI-treated cells, we observed an upregulation of BIM, which is also generally known to be increased in CML cells treated with dasatinib or imatinib [35], whereas we detected cleavage of PARP in cells treated with proteasome inhibitors and in the combination treatment. The gene discussed is PARP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.